Table 2.

Distribution of potentially prognostic factors

Prognostic factors	Subgroups	Number of patients	(%)
Patient-related factor
Gender	Female	367	45
	Male	441	55
Age (years)	≤64	416	51
	≥65	392	49
ECOG performance status	PS 0–2	580	72
	PS 3–4	228	28
Neurological deficits	Frankel D, E	765	86
	Frankel A, B, C	43	14
Laboratory data1	Normal	185	23
	Abnormal2	457	57
	Critical3	150	19
Primary-site-related factor
Primary site	Slow growth	126	16
	Moderate growth	224	28
	Rapid growth	458	57
Visceral or brain metastasis4	No	121	15
	Nodular metastasis	428	53
	Disseminated metastasis	245	30
Remaining primary lesion	No	272	34
	Yes	536	66
Previous chemotherapy	No	354	44
	Yes	454	56
Skeletal-metastasis-related factor
Location of skeletal metastasis	Axial bone	528	65
	Axial bone and proximal limb	257	32
	Spreading to distal limb	23	3
Multiple skeletal metastases	No	200	25
	Yes	608	75
Pathological fracture	No	545	68
	Yes	261	32

ECOG, Eastern Cooperative Oncology Group.

¹792 subjects.

²Abnormal: CRP ≥ 0.4 mg/dL, LDH ≥ 250 IU/L, or serum albumin <3.7 g/dL.

³Critical: platelet count <100,000/μL, serum calcium level ≥10.3 mg/dL, or total bilirubin ≥1.4.

⁴794 subjects.